eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all . Please read our guidelines before submitting your own eLetter.
Research ArticleCANCER
Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death
- View ORCID ProfileS. Busker1,
- W. Qian2,
- M. Haraldsson3,
- B. Espinosa1,
- L. Johansson3,
- View ORCID ProfileS. Attarha4,
- I. Kolosenko5,*,†,
- J. Liu6,
- View ORCID ProfileM. Dagnell1,
- D. Grandér5,‡,
- View ORCID ProfileE. S. J. Arnér1,
- View ORCID ProfileK. Pokrovskaja Tamm5 and
- View ORCID ProfileB. D. G. Page4,7,§
- 1Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
- 2Laboratories for Chemical Biology Umeå, Chemical Biology Consortium Sweden, Umeå University, Umeå, Sweden.
- 3Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
- 4Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
- 5Department of Oncology and Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.
- 6Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
- 7Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
- ↵§Corresponding author. Email: brent.page{at}ki.se
See allHide authors and affiliations
Science Advances 20 Mar 2020:
Vol. 6, no. 12, eaax7945
DOI: 10.1126/sciadv.aax7945
Vol. 6, no. 12, eaax7945
DOI: 10.1126/sciadv.aax7945
S. Busker
1Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
W. Qian
2Laboratories for Chemical Biology Umeå, Chemical Biology Consortium Sweden, Umeå University, Umeå, Sweden.
M. Haraldsson
3Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
B. Espinosa
1Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
L. Johansson
3Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
S. Attarha
4Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
I. Kolosenko
5Department of Oncology and Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.
J. Liu
6Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
M. Dagnell
1Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
D. Grandér
5Department of Oncology and Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.
E. S. J. Arnér
1Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
K. Pokrovskaja Tamm
5Department of Oncology and Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.
B. D. G. Page
4Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
7Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Submit a Response to This Article
No eLetters have been published for this article.